Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Chemotherapy, Pembrolizumab, and Propranolol in Advanced Esophageal/Gastroesophageal Junction Adenocarcinoma Patients

NCT05651594 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT05651594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05651594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Chemotherapy, Pembrolizumab, and Propranolol in Advanced Esophageal/Gastroesophageal Junction Adenocarcinoma Patients
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
March 7, 2023
Completion date
March 30, 2029
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage ii esophageal adenocarcinoma ajcc v8, clinical stage iii esophageal adenocarcinoma ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iv esophageal adenocarcinoma ajcc v8, clinical stage iv gastroesophageal junction adenocarcinoma ajcc v8, locally advanced esophageal adenocarcinoma, locally advanced gastroesophageal junction adenocarcinoma, metastatic esophageal adenocarcinoma, metastatic gastroesophageal junction adenocarcinoma, unresectable esophageal adenocarcinoma, unresectable gastroesophageal junction adenocarcinoma